1. A Phase III Multi-Center Randomized Double-Blind, Placebo-Controlled Trial of the Ex-Vivo Treatment with CGT003 of Peripheral Vein Grafts in Patients Undergoing Peripheral Arterial Bypass Graft Procedures, Protocol #CGTOOJ-03

2. A Randomized Controlled Clinical Trial of the Effect of a High Dose Combination of Folic Acid, Vitamin B6 and B12, on Arteriosclerotic Cardiovascular Disease Outcomes in Chronic, Stable Renal Transplant Recipients. (An Ancillary Study of the FAVORIT trial)

3. A Randomized, Double-Blind, Placebo Controlled, Multi-Center Safety and Efficacy Trial of LJP 394 in Systematic Lupus Erythematosus (SLE) Patients with a History of Renal Disease. Protocol # UP 394-90-10


5. Multi-Center, Randomized, Double Blind, Placebo-Controlled, Efficacy and Safety Study of the Effects of Oral Tolvaptan in Patients with Hyponatremia. Protocol # I56-02-235

6. A Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Trial of CII Oral Tolerance Induction in Rheumatoid Arthritis Patients of NSAIDs.

7. Epidemiologic Study of the Natural History of Fabry Disease. Protocol # AGAL-014-01

8. Endoscopic Delivery of Energy to the Gastric Cardia for the Treatment of Gastroesophageal Reflux Disease, the Stretta Procedure.


10. An Evaluation of the Endonetics Gatekeeper System, in the Treatment of Patients with Gastroesophageal Disease (GERD).

11. Safety and Efficacy of Recombinant Human Interleukin-10 (TENOVI L) in Prevention of Post-ECRP Acute Pancreatitis in Subjects with Increased Risk.

13. Clinical Protocol for a Randomized, Double-Blinded, Placebo-Controlled, Parallel, Multi dose comparison of the Effects of Celecoxib 200mg BID and Placebo in Patients with Ulcerative Colitis in Remission.


15. A Double-Blind, Randomized, Controlled Study to Evaluation the Immunogenicity and Safety of XXX Herpes Simplex Candidate Vaccine, (XXX) in Healthy HSY Seronegative and Seropositive Female Subjects (10-17 years old).

16. A Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Single Dose Study to Evaluate the Safety and Efficacy of XXX in Acute Treatment of Migraine Headaches.


18. A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 18 month Study of the Efficacy of XXX, in Patients with Mild-to-Moderate Dementia of the Alzheimer’s type.

19. A Double-Blind, Placebo-Controlled, 12 Week Safety Study to Assess the Effect of XXX (100mg QD) on Spermatogenesis and Reproductive Endocrine Parameter in Healthy Adult Male Subjects.

20. A Safety and Efficacy Study of Subjects with Age Associated Memory Impairment (AAMI).

21. A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Subjective Response to Treatment with Ramelteon (XXX) in Adult Subjects with Chronic Insomnia by Utilizing an Interactive Voice Response (IVRS) for Collecting Diary Data.

22. A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS) in Combination with XXX in Subjects with Type 2 Diabetes.

23. A 24 Week Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Added to the Therapy of Patients with Type 2 Diabetes Poorly Controlled on Insulin.

24. A Double-Blind, Randomized, Placebo-Controlled 4 Week Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXX and its Active Metabolite, in Subjects with Type 2 Diabetes Mellitus.

25. An Open-Label Study to Examine the Long-Term Effect on Glucose Control (Hgb A1C), Safety, and Tolerability of XXX Given Two Times a Day to Subjects with Type 2 Diabetes.
26. A Multi-Center Study to Determine the Exposure to Cigarette Smoke of Adult U.S. Smokers, who Spontaneously Switched to Lower or Higher FTC Tar Delivery Cigarettes, Phillip Morris USA Inc.

27. A Double-Blind, Randomized, Parallel Group Study, to Evaluate the Safety, Tolerability, and Efficacy of XXX, Alone or Co-administered with Atorvastatin, in Subjects with Primary Dyslipidemia.

28. A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Examine Safety and Pharmacokinetics of XXX Long-Acting Released, Administered Weekly in Subjects with Type 2 Diabetes Mellitus.

29. A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Study to Assess the Safety and Efficacy of FS-67 in Subjects with Muscle Strain.


32. A Phase III, Investigator-Blind, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of XXX Sprinkle PO QD for 7 Days Compared to Penicillin VK 10mg/kg PO QID for 10 Days in the Treatment of Tonsillitis and/or Pharyngitis Secondary to Streptococcus Pyogenes in Pediatric Patients.

33. An Open-Label Study of the Efficacy and Safety of 5mg and 10mg XXX in Patients with Overactive Bladder Symptoms.

34. A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Examine Safety and Pharmacokinetics of XXX Long-Acting Release Administered Weekly in Subjects with Type 2 Diabetes Mellitus.

35. A Multi-Center, Placebo-Controlled, Randomized, Double-Blind, Subject Initiated Study of the Safety and Efficacy of a Single Topical Iontopheretic Application of Acyclovir 5% Cream with an Open Label Conventional Therapy Treatment Arm, and a Blinded Evaluator, for the Episodic Treatment of Recurrent Herpes Labialis.

36. A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of XXX XR (Extended Release) in Patients with Restless Leg Syndrome.

37. A U.S. Randomized Questionnaire-Based Trial Assessing the Impact of the Availability of Inhaled Insulin of Therapeutic Choice in Patients with Sub-Optimally Controlled Type 2 Diabetes.
38. A 12 Week, Dose-Ranging, Double-Blind, Randomized, Placebo-Controlled, Parallel-group study to Assess the Safety and Efficacy of XXX in Obese Patients.


42. Efficacy and Safety of 10mg XXX for Treating Frequent Heartburn in Frequent Suffers.

43. A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Cross-Over Study to Determine the Consistency of Response for XXX (Sumatriptan 85mg/ Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks.

44. A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study of the Efficacy and Safety of Oral Doses of 20mg XXX, When used on-Demand for Pain.

45. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate Safety and Efficacy of XXX in Patients with Mild-to-Moderate Alzheimer’s Disease.

46. A Double-Blind, Randomized, 6 Month Evaluation of the Safety and Efficacy of Topical Alprostadil in Hysterectomized Women with Female Sexual Arousal Disorder (FSAD).

47. A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled, Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (XXX) Compared with Placebo in the Treatment of Generalized Anxiety Disorder (Gold Study).

48. A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Active – Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (XXX) as Monotherapy in the Treatment of Patients with Major Depressive Disorder (Diamond Study).

49. A Double-Blind, Randomized, Placebo-Controlled, Study of the Efficacy, Safety, and Tolerability of 8 Week Treatment of XXX 8mg(QHS) in Sleep Disturbed, Community Dwelling, Mild-to-Moderately Severe Alzheimer’s Disease Subjects.

50. A Forty-Eight Week, Randomized Discontinuation Trial of Flibanserin in Women with Hypoactive Sexual Desire Disorder, Containing an Open-Label Flexible Dose Period, Followed by an Double-Blind, Randomized, Placebo-Controlled Period.
51. A Long-Term, Open-Label, Safety Extension Study of the Combination of Fenofibric Acid and Statin Therapy for Subjects with Mixed Dyslipidemia.
52. Long-Term, Open-Label, Safety Study of Oral Almotriptan Malate 12.5mg in the Treatment of Migraines in Adolescents.
53. The Rembrandt Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed and Flexible XXX Dose Arm Study, to Assess Efficacy and Safety of XXX Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease.
54. A Phase II Study Evaluating the Efficacy and Safety of a Unique Intravenous Iron Preparation in the Treatment of Restless Leg Syndrome (RLS).
55. A Double-Blind, Randomized, Parallel, Efficacy Study Evaluating Losartan Potassium, Alone or in Combination with Hydrochlorothiazide Versus Placebo in Obese Patients with Elevated Systolic and Diastolic Blood Pressure.
56. A Validation Study of the COPD-PS in a Community Based Sample
57. A Randomized, Open-Label, Multi-Center, Comparator-Controlled, Study to Examine the Effects of Eventide Long-Acting Release on Glucose Control (Hgb A1C) and Safety, in Subjects with Type 2 Diabetes Mellitus Managed with Diet Modification and Exercise and/or Oral Antidiabetic Medications.
59. A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Dosed and Dose Levels of XXX in Female Patients with Irritable Bowel Syndrome with Diarrhea.
60. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study of the Efficacy, Tolerability, and Safety of XXX in the Treatment of Pain Associated with Tendonitis or Bursitis of the Shoulder, Knee, or Elbow.
61. A Phase III, 24 Week, Multi-Center, Open-Label, Randomized, Controlled Trial Comparing the Efficacy and Safety of Prandial Inhalation of Technosphere /Insulin in Combination with Metformin or Technosphere/ Insulin Alone Versus 2 Oral Antidiabetic Agents (Metformin and Secretagogue) in Subjects with Type 2 Diabetes Mellitus Sub-Optimally Controlled on Combination Metformin and Secretagogue.
62. A Randomized, Double-Blind, Active-Controlled, Vehicle-Controlled, Subject Initiated Study Comparing Efficacy and Safety of XXX Versus Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis. A Multinational, Multi-Center Phase III Study.

63. A 24 Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of XXX 50mg and 100mg Each Evening in Premenopausal Women with Hypoactive Sexual Desire Disorder.

64. A Multi-Center, Randomized, 1Week, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients with Major Depressive Disorder, Who Completed 8 Weeks of Open-Label Treatment with XXX 100mg Once a Day.

65. A Multi-Center, Double-Blind, Parallel Group, Fixed Dose, 4-Arm Placebo and Paroxetine Controlled 8 Week Efficacy Study of 2 Oral Doses of XXX (175mg or 350mg BID) in Adult Outpatients with Major Depression Disorder.

66. A 12 Month, Open-Label, Safety Trial of XXX 50mg to 100mg Daily in Women with Hypoactive Sexual Desire Disorder.

67. A 104 Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Obese Patients.

68. Effect of Septal Closure of Atrial PFO on Events of Migraine with XXX Device.

69. A Phase III, Prospective, Observer-Blind, Randomized, Controlled, Multi-Center, Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline Biologicals’ XXX, XXX, and XXX Compared to Sanofi Pasteur’s XXX and XXX, When Administered as a Booster Vaccine in Adults Aged 19-64.


72. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of the Efficacy and Safety of XXX in Adult Subjects with Type 2 Diabetes Mellitus.

73. Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Absorbed in Persons > 65 Years of Age.

74. A clinical Study to Evaluate the Safety and Efficacy of XXX 12 hour 5mg Loratadine Tablet Versus Placebo Tablet in the Treatment of Allergic Rhinitis.

75. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel, Dose Ranging Study of the Safety and Efficacy of XXX in Patients with Painful Diabetic Peripheral Neuropathy.
76. Open-Label, Multiple Dose Study of the Safety and Efficacy of XXX in Adults with Pain due to Osteoarthritis of the Knee.

77. A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of 14 day Treatment with XXX 15mg or 30mg Once a Day, in Frequent Nighttime Heartburn.

78. A Randomized, Double-Blind, Placebo-Controlled, Dose Titration Study to Assess the Safety, Tolerability, and Efficacy of XXX in Persons with Multiple Sclerosis with Cognitive Impairment.

79. A Double-Blind, Multi-Center, Randomized, Parallel Group, Yearlong Study to Assess the Efficacy and Safety of XXX or XXX of XXX Administered Orally Once Daily with a Reduced Calorie Diet in Obese Males and Females.

80. Efficacy and Safety of XXX of XXX on Sleep Maintenance Insomnia with a Sub-Study of the Effect of XXX, on Stable Type 2 Diabetes Mellitus: A 12 Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial.

81. A Phase III, 53 Week Study on XXX Efficacy and Safety of XXX: 26 Week, Randomized, Parallel-Group, Double-Blind, Placebo (13 Weeks), and XXX (26 Weeks) Controlled, Multi-Center Study of XXX, Controlled Safety Follow-Up in Subjects with Osteoarthritis of the Knee and 1 Week Post-Treatment Safety Follow-Up.

82. A Phase II Randomized, Double-Blind, Placebo and Positive Controlled, Multi-Center, Parallel Group Proof of Concept Study of the Analgesic Effects of XXX in Adult Patients with Chronic Low Back Pain.


84. Double-Blind, Parallel-Group, Comparison of 23mg XXX Sustained Release to 10mg XXX Immediate Release in Patient with Moderate to Severe Alzheimer’s Disease.

85. Efficacy and Safety of 2mg/day of XXX on Sleep Maintenance Insomnia with a Sub-Study of the Effect of XXX on Stable Type 2 Diabetes Mellitus: A 12 Week, Multi-Center Randomized, Double-Blind, Placebo-Controlled Study.

86. Open-Label Study of the Effect of Daily Treatment with XXX in Subjects with Dementia of the Alzheimer’s Type.

88. A Phase II, Multi-Center, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects with Uncomplicated Acute Influenza.

89. A Randomized, Double-Blind, Phase III, Study of the Efficacy and Safety of XXX in Subjects Requiring NSAID Treatment.

90. A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effects of DHA on Cognitive Functions in the Elderly.

91. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II/III, Study to Evaluate the Efficacy and Safety of XXX and Placebo Given Orally for 12 Weeks for the Treatment of Opioid-Induced Constipation (OIC) in Patients with Chronic Non-Cancer Pain.

92. A Phase III, Randomized, Multi-Center, Double-Blind, Allopurinol-Controlled, Study Assessing the Efficacy and Safety of Oral XXX in Subjects with Gout.

93. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Study Investigating the Efficacy and Safety of a Fast Dissolving (XXX) Formulation of XXX for the Treatment of Nocturia in Adults.

94. A Phase III, Randomized, Active-Controlled, Modified Double-Blind, Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to a 23-Valent Polysaccharide Vaccine in Adults 60-64 Years Old who are Naive to 23-Valent Polysaccharide Vaccine.


96. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study Comparing the Safety and Efficacy of Multiple Doses of XXX Sustained Release,IXXX Sustained Release, and Placebo in Obese Subjects with Type 2 Diabetes Mellitus.

97. A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Dose Range Finding, Parallel-Design, Phase II Trial of Oral XXX Administered to Patients with Irritable Bowel Syndrome with Constipation.

98. A 2 Week, Randomized, Double-Blind, Placebo and Positive Controlled, Parallel Group, Multi-Center, Study to Assess the Efficacy and Tolerability of XXX in Patients with Moderate to Severe Pain Due to Osteoarthritis.

99. Phase II, Randomized, Double-Blind, Placebo and Active Controlled, Multi-Center, Parallel Group, Proof of Concept Study of the Analgesic Effects of XXX in Adult Patients with Chronic Low Back Pain.
100. A Multi-Center, Randomized, Double-Blinded, “Crossover” Design Study to Evaluate the lipid altering Efficacy and Safety XXX Combination Tablet Compared to XXX+ Simvastatin Co-administration in Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia.

101. A Double-Blind, Randomized, Study to Evaluate the Efficacy and Safety of XXX 50mg or Placebo When Co-Administered with Statins in Subjects with Hypercholesterolemia, With an Optional Open-Label Extension.

102. A Phase III, Controlled, Multi-Center, Study to Evaluate Antibody Persistence at 1,3,5, and 10 years following administration of single dose Tdap Vaccine to Healthy Subjects, 19 Years of Age and Older in the Study XXX.

103. A Phase III, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine (13vpnc) When Administered concomitantly with Trivalent Inactivated Influenza Vaccine in Healthy Adults 50-59 Years of Age Who Are Naïve to 23-Valent Pneumococcal Polysaccharide Vaccine and to Evaluate the Immune Response of a Second Dose of 13vpnc Administered 5 Years After Initial 13 vpnc Vaccination.

104. Double-Blind, Parallel-Group, Comparison of 23mg of XXX Sustained Release to 10mg XXX Immediate Release in Patients with Moderate to Severe Alzheimer’s Disease.

105. A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study with Open-Label Follow On, to Evaluate the Efficacy, Safety, and Tolerability of PSD502 in Subjects with Premature Ejaculation (PE).

106. Randomized, Double-Blind, Parallel-Group, Multi-Center, Study to Compare the Glycemic Effects, Safety, and Tolerability of XXXX: Long-Acting Release to Those of XXXX and XXXX in Subjects with Type 2 Diabetes Mellitus Treated with XXXX.

107. A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Dose Response of XXXX Compared to Open-Label XXXX in Patients with Hypercholesterolemia.

108. A Phase III Randomized, Double-Blind, Parallel-Design Study Comparing Multiple Doses of XXXX to Placebo and Their Single Agent XXXX and XXXX Constituents for the Treatment of Obesity in Adults.

109. Evaluation of XXXX on Carotid Intima-Media Thickness in Subjects with Type Ila and IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial.

110. A Phase III, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Immunogenicity of 2 Dose Series of XXXX Vaccine Antigen in Association with AS03 Adjuvant in Adults.
111. A Phase III, Flexible Dose Titration Followed by Randomized Double-Blind Study of Controlled Release XXXX Compared to Placebo in Patients with Osteoarthritis.

112. A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of XXXX Administered in Conjunction with XXXX in Obese and Overweight Subjects.


114. A 52 Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety And Efficacy of XXXX in Obese and Obese Patients.

115. A One Year Open-Label Study Assessing the Safety and Tolerability of XXXX in Patients with Major Depressive Disorder.

116. The Efficacy and Safety of XXXX in the Treatment of Osteoarthritis of the Knee.


119. A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of XXXX Administered in Conjunction with XXXX in Obese and Overweight Subjects.

120. A Multi-Center, Randomized, Parallel –Group, Placebo-Controlled, Efficacy and Safety Trial to Evaluate the Effect of XXXX on Weight in Obese and Overweight Subjects.

121. A Randomized, Double-Blind, Placebo-Controlled Subjective study to Assess the Efficacy of XXXX in Patients with Primary Insomnia Characterized by Difficulty Maintaining Sleep.

122. A Phase I, Open-Label Study to Assess the Safety, Extent, and Route of BMS747158 Nuclear Imaging Product.

123. A Long Term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD) in SPECT and PET.

124. A Phase IV Safety Study to Provide Data on Potential Systematic and Pulmonary Hemodynamic Effects Caused by Administration of XXXX in Patients who Undergo Right Heart Cardiac Catherization.
125. A Phase IV Safety Study of Patients with Cardiovascular Disease who have Echocardiography with XXXX.


127. A Phase III Open-Label, Multi-Center, Trial to Evaluate the Efficacy and Safety of XXXX Myocardial Perfusion Imaging (MPI) in the Pediatric Population with Kawasaki Disease.

128. A Phase IV Multi-Center, Open-Label, Follow up Study to Assess Incidence of Nephrogenic Systematic Fibrosis in Patients with Moderate to Severe Kidney Disease Undergoing Magnetic Resonance Imaging (MRI) with XXXX in Clinical Practice.

129. Retrospective Observational Database to Compare Mortality in Intensive Care Unit (ICU) Patients Undergoing Echocardiography with and without XXXX.

130. A Phase III, Open-Label, Multi-Center, Study for the Assessment of Myocardial Perfusion using Positron Emission Tomography (PET) Imaging of BMS747158 Injection in Patients with Suspected or Known Coronary Artery Disease (CAD).

131. A Multi-Center, Phase II, Open-Label Trial to Determine Optimal Imaging Parameters and Assess the Safety of LMI1195-101 in Heart Failure Subjects.

132. A Phase III, Open-Label, Multi-Center, Single Dose, Study to Assess the Diagnostic Efficacy of BMS747158 in Patients with Suspected of Known Coronary Artery Disease (CAD).

133. A Phase II, Open-Label, Randomized, Multi-Center Study for the Development of One-Day Rest/Stress Cardiac PET perfusion Imaging Protocols in Patients with Ischemia.